Scope:

Given the safety and tolerability profiles associated with current osteoporosis therapies, as well as the low drug-treatment and compliance rates, significant unmet need remains in the field of osteoporosis. A number of novel osteoporosis therapies are set to launch over the next five years, and it is anticipated that they may at least partially address current unmet needs. 


Related Reports

Osteoporosis | Current Treatment | US | 2016

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with thes...

View Details

Osteoporosis | Current Treatment | Detailed, Expanded Analysis (US)

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with th...

View Details

Osteoporosis | Current Treatment | Detailed, Expanded Analysis Treatment Algorithms Claims Data Analysis (US)

A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, espe...

View Details

Osteoporosis | Landscape & Forecast | Disease Landscape & Forecast

Patients with osteoporosis are at increased risk of suffering fractures due to a loss in bone strength. These fractures, in turn, place a considerable burden on public health systems. The osteopo...

View Details